Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 2,101–2,162 of 2,162
Cytokine Storm, Inflammation and Immunity in COVID-19
Datta, C., & Bhattacharjee, A. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_9
Zhang, P. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106032
Stadtmüller, A., Grampp, R., Marianantoni, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699692
Renaissance of Phase I trials in India: Lessons from global trials and tribulations of TGN1412
Bhatt, A., & Davis, S. (2026) · Perspectives in Clinical Research · doi:10.4103/picr.picr_413_25
“[3] Two volunteers had prolonged cardiovascular shock, developed acute respiratory distress syndrome, and required intensive organ support for a long duration.”
InfluentialYoshitomi, R., & Sugiura, S. (2026) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2026.01.001
Matsumoto, M., Polli, J. R., Swaminathan, S. K., Datta, K., Kamperschroer, C., Fortin, M. C., Salian‐Mehta, S., Dave, R., Yang, Z., Arora, P., et al. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106038
Opinion: Why paediatric rheumatologists need to understand inborn errors of immunity
Abinun, M., & Owens, S. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1755761
Development of autologous in vitro vascular models for use in preclinical biotherapeutic development
Lund, E., Silvester, A., Thwaites, D., Bennour, Y., McKechnie, M., Beaumont, R., Munday, J., & Cooper, C. (2026) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2026.100143 · Cited by 1
Nehul, S., Nagaraj, S. K., Narayan, R., et al. (2026) · Archives of Virology · doi:10.1007/s00705-026-06557-w
“Injected antibodies in patients can be recognized as foreign particles by the host immune response and induce a strong immune response [10].”
Bispecifics: The future of therapeutic antibodies
Davis, J. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00093-5
Tallón, A., Laspidea, V., Ausejo‐Mauleon, I., de la Nava, D., Labiano, S., González-Huarriz, M., Zalacaín, M., Patiño‐García, A., Villanueva, H., Fueyo-Margareto, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.01.708858
“However, mAb-based anti-cancer therapies typically require multiple systemic doses, leading to on-target/off-tumor toxicities 11–13 .”
Rethinking Immune Checkpoint Inhibition in Cancer
Bakács, T., & Anderson, C. C. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70106 · Cited by 2
Rajagopal, D., Ieong, K. S., Mate, R., & Vessillier, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736130
Hofstetter, M., Volta, L. G., Koch, C., Rey, M. G., Maurer, M., Gonullu, N. G., Pellegrino, C. E., Gobbi, C., Schneiter, F., Manfredi, F., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0672
“However, antibody-based engagement of CD28 has progressed cautiously, largely due to massive cytokine release induced by a super-agonistic CD28 IgG4 (TGN1412) in healthy volunteers (65, 66).”
Donnou‐Fournet, E. (2016) · theses.fr (ABES) · doi:10.70675/b7746b6bz4288z4926z9752z74ad6d510693
Génération et analyse d’un nouveau modèle de la maladie APECED par déficience pour Aire chez le rat
Ossart, J. (2018) · theses.fr (ABES) · doi:10.70675/96586792zd58bz497dza907zfe0a41d8d94d
Fumet, J.-D., Dugage, M. R., Danlos, F.-X., Hueso, T., Pinato, D. J., Luke, J. J., Melero, I., LoRusso, P. M., Brody, J., Harrington, K. J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.006 · Cited by 2
CD28 : nouvelles données sur un récepteur majeur de la costimulation lymphocytaire T
Morin, S. O. (2017) · theses.fr (ABES) · doi:10.70675/cb01635fz2f63z43e2zad0cz210485c4c5cf
Déterminants moléculaires de la pharmacocinétique des anticorps thérapeutiques
Brachet, G. (2017) · theses.fr (ABES) · doi:10.70675/8a131ef8z9b1az469fzb97aze35914486b73
Boucault, L. (2018) · theses.fr (ABES) · doi:10.70675/e59ab1f0zdf8az4b41za5f9z1f1d0e55aa46
Vinot, P.-A. (2018) · theses.fr (ABES) · doi:10.70675/8d700747z53d5z4ad2z91fbz840e35448ca7
Le rôle de GDF11 dans les leucémies aiguës myéloïdes
Siavellis, J. (2021) · theses.fr (ABES) · doi:10.70675/b953e730zc0bez4347za9e4z561daebbcc2d
Sierocki, R. (2020) · theses.fr (ABES) · doi:10.70675/a21eef57z41b9z4748z9da6z2af2b38799d6
Analyse protéomique et interactomique de l'activation des lymphocytes T humains primaires
Nicolas, P. (2021) · theses.fr (ABES) · doi:10.70675/defcbd86z76d7z43bfz9103zb8a743a479f5
Bonnin, E. (2022) · theses.fr (ABES) · doi:10.70675/fd80c953z7ef5z4ff7z8413z3bd284faeed4
Etude des mécanismes de contrôle des cellules tumorales par les cellules Natural Killer
Fenis, A. (2024) · theses.fr (ABES) · doi:10.70675/747c59caz7a79z4064z989cz9dd2bc8bd27e
CAR T cell engineering approaches to minimise toxicities
Hogben, E., Schurich, A., & Graham, C. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.11021
Li, Q., Liu, Y., Wang, Y., & Li, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1823374
“For instance, the CD28 superagonist TGN1412 caused life-threatening CRS in six volunteers during a Phase I clinical trial (34).”
Besbassi, H. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.64898/2026.05.05.722920
“…if its predicted peak IL-6 falls simultaneously within all three published clinical ranges: • TGN1412 3,000-100,000 pg/mL (Suntharalingam 2006) [4] • OKT3 200-2,000 pg/mL (Chatenoud 1989, Abramowicz 1989, Ferran 1990) [5, 6, 7] These ranges were taken from the published clinical sources cited…”
InfluentialJin, Y., & Yao, H. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0065 · Cited by 1
Realizing the potential of agonistic antibody immunotherapy
Cragg, M. S., Yu, X., Paluch, C., & Davis, S. J. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01442-2 · Cited by 2
“However, 90 minutes after receiving a dose of the antibody, six healthy young volunteers each suffered a systemic inflammatory response leading to CRS and multi-organ failure 149,150 .”
AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint
Kuncewicz, K., Upadhyay, S., Zhu, R., Duan, H., & Gabr, M. T. (2026) · Advanced Science · doi:10.1002/advs.75892 · Cited by 2
“Moreover, modulation of costimulatory receptors such as CD28 carries unique safety considerations, as excessive receptor activation can trigger severe cytokine release syndromes [ 20 ].”
Henriksen, I. W., Bartholdy, C., Koch, J., Stefanova, D. V., Hansen, C. H. F., & Hansen, A. K. (2026) · Clinical and Translational Science · doi:10.1111/cts.70593
“Consequently, immune responses and the effect of drug candidate treatment in SPF mice can be completely different to the clinical settings, leading to a lack of efficacy or even toxicological outcomes in the clinical setting [20, 21].”
Fletcher, S., Biswas, E. E., & Biswas, S. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.01.729313
What Is Cancer? 4 Cancer Immunology
Yokosuka, T., Nishi, W., Nishikawa, T., Matsushima, R., Yoshida, Y., Toyota, H., Furuhata, M., Nishijima, H., Machiyama, H., Takeuchi, A., et al. (2026) · Springer eBooks · doi:10.1007/978-981-95-6537-5_4
A need for pragmatism in preclinical aging and longevity research
Austad, S. N. (2026) · Nature Aging · doi:10.1038/s43587-026-01151-w
Integrating new approach methodologies into human-relevant preclinical research
Tong, L., Zhao, H., Baldran-Groves, L., Wang, K., Ai, X., Liang, Q., Luo, W., Wang, B., Fan, Y., 刘海鹰, et al. (2026) · hLife · doi:10.1016/j.hlife.2026.06.003 · Cited by 1
Kraft, T. E., Marrer‐Berger, E., Belli, S., Haegel, H., Schneider, A., Giusti, A. M., Bscheider, M., Jacob, W., Weisser, M., Blanco, L., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70366
“6,8,9 The minimal biological effect of T-cell engagers may be evaluated in a variety of in vitro assays, such as for T-cell activation, cytokine release and cytotoxicity.”
Santiago-Sánchez, G. S., Rosato, F., Fabian, K. P., Padget, M. R., Lee, J.-M., Karzai, F. H., Schlom, J., Gulley, J. L., Hamilton, D. H., Lee, J. K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014518
Sequential infection reprograms the immune landscape to shape future responsesPreprint
Guo, M., Bouzaher, Y. H., Abd-Rabbo, D., Quevedo, R., Elsaesser, H. J., Xu, W., Liu, M., Izzati, F. N., Ciudad, T., Bianca, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.26.734836
Sibilia, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.05.007
Yang, Y., Li, R. C., Lyu, C., Zhang, W., Sun, Y., & Xie, R. (2026) · Journal of International Medical Research · doi:10.1177/03000605261471751
“8 These serious events emphasized that immune activation requires strict control when employing any immune activator.”
Stadtmüller, A., Grampp, R., Marianantoni, G., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1869344
“In a fi rst study we used the superagonistic anti-porcine CD28 mAb 4D12 at a dose of 10 m g/kg body weight (bw) (14), i.e. well below the 100 m g/ kg bw, which induces a cytokine release syndrome in humans (15) and pigs (16).”
Fifteen challenges for generative AI applications to cell biology
Dupire, L., Khan, A. A., Karaletsos, T., Kelley, S., Lundberg, E. K., Ma, J., Paull, E., Quake, S. R., Rabadán, R., Cassius, R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.07.004 · Cited by 4
Immunotherapy of malignant melanoma using T cell–activating microbeads
Hassan, N. T., Löffler, J., dos Santos, A. S., Wohlfarth, J., Wußmann, M., Schellhammer, L., Berg, J. V., Groeber-Becker, F., Kerkau, T., Schilling, B., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag191
Williams, G. S., Pribul-Allen, P., Kurach, G., Edziwa, V. C., Kernohan, A. B., Gower, J. K., Gandhi, M., Cortina, R., Euesden, J., Kennedy, J., et al. (2026) · Journal of Immunological Methods · doi:10.1016/j.jim.2026.114109
Integration of biological avatars and digital twins for “ex vivo clinical trials”
Howe, C. L. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106467
“95 In addition to the inherent scientific limitations of extrapolating human responses from nonhuman models, 7 the historical reliance on animal testing, especially research involving nonhuman primates and other large animal models, is fraught with ethical concerns.”
Gößwein, M., Ulmert, I., Rosshart, S. P., & Coquet, J. M. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20261517
Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells
Willier, S. M., Farber, J. L., Ispyrlidou, T., Wilhelm, J., Mayer, E., Stenger, D., Seiferling, J., Brien, A. E., Nikolaides, S., Ferrada‐Ernst, P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78312-3
CD40 Stimulation and Antitumor Effects
Wilkins, D. E. C., & Murphy, W. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_13
The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis
Lahiff, C. J., Moss, A. C., & Cheifetz, A. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1677-1_2
Tynjälä, P. (2008) · Työväentutkimus Vuosikirja
Biologiske laegemidler til behandling af ikkecancerrelaterede sygdomme
Skov, L., & Bendtzen, K. (2008) · Ugeskrift for Læger
Development of immunogenicity models in mice for improved risk assessment of biopharmaceuticals
Granath, B. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Solution structure of interleukin-1β bound to a potential therapeutic antibody
Wilkinson, I. C. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Allogeneic and Autologous Transplantation Therapy of Cancer: Converging Themes
Fowler, D. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_19
“It is certainly possible that humans are particularly sensitive to the deleterious effects of dramatic and specific T-cell responses; it is also important to note that such responses in the past have not been predicted from animal modeling, as was observed in the uniform development of severe cytokine storm in a phase…”
Background
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.